ArticleJournal of gastrointestinal oncology2018
Expression of miR-520c in intestinal type gastric adenocarcinoma.
Article in Journal of gastrointestinal oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- Influence of Reference Gene Selection on miRNA Quantification by RT-qPCR in Human Placental Samples.British journal of biomedical science · 2025Article
- Development of nomograms for predicting the survival of intestinal-type gastric adenocarcinoma patients after surgery.Scientific reports · 2023Article
- Article
- miR-193a Directly Targets PSEN1 and Inhibits Gastric Cancer Cell Growth, the Activation of PI3K/Akt Signaling Pathway, and the Epithelial-to-Mesenchymal Transition.Journal of oncology · 2021Article
- Radiotherapy benefited the survival of patients with intestinal-type gastric adenocarcinoma: a SEER population-based study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Contribution of DNA methylation and EZH2 in SRBC down-regulation in gastric cancer.Molecular biology reports · 2020Article
- MiRNAs as Novel Adipokines: Obesity-Related Circulating MiRNAs Influence Chemosensitivity in Cancer Patients.Non-coding RNA · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs are small non-coding RNAs that participate in post-transcriptional gene regulation in cells thereby playing active role in pathological conditions and have been nominated as new class of biomarkers in disease including cancer. miR-520c has been reported as potential oncogenic micro-RNA in several previous studies. Gastric cancer is the most common cancer of digestive tract and the fourth prevalent cancer worldwide with the intestinal-type gastric adenocarcinoma (IGA) the dominant type of gastric malignancies. This study aimed to explore miR-520c putative role, in IGA and patient's clinicopathological features.
methodsTotal RNA was first extracted from 42 pairs of IGA tissues and relevant non-tumorous adjacent tissues. cDNA was synthesized from extracted RNAs using specific primers for miR-520c. The level of miR-520c was quantified using SYBER Green Real-Time PCR master mix. The relationship between miR-520c expression and clinicopathological features were examined.
resultsOur study resulted in no differential expression of miR-520c in IGA. There was no significant correlation between miR-520c expression and clinicopathological features including tumor grade, genus and age groups.
conclusionsTo our knowledge, this is the first report about exploring miR-520c expression in IGA tissue samples. Our results do not verify miR-520c previously established oncogenic role in IGA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.